Updates are available Correction dated 2020-04-28
Click to view Correction: https://doi.org/10.1186/s40035-020-00193-3
-
Authors
Reichmann, Heinz
,
Lees, Andrew
Rocha, José-Francisco
Magalhães, Diogo
Soares-da-Silva, Patrício http://orcid.org/0000-0002-2446-5078
-
Funding
Funding for this research was provided by:
BIAL - Portela & Ca, S.A. (n/a)
- License Information
-
More Information
Article History
Received: 6 December 2019
Accepted: 17 February 2020
First Online: 4 March 2020
Change Date: 28 April 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: Institutional review boards at the participating sites approved the protocol and the trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines. All patients provided written informed consent.
: Not applicable.
: HR reports acting on Advisory Boards, gave lectures and received research grants from Abbott, Abbvie, Bayer Health Care, BIAL, Boehringer/Ingelheim, Brittania, Cephalon, Desitin, GSK, Lundbeck, Medtronic, Merck-Serono, Novartis, Orion, Pfizer, TEVA, UCB Pharma, Valeant, and Zambon. AJL is funded by the Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology and reports consultancies from Britannia Pharmaceuticals and BIAL. He also reports grants and/or research support from the Frances and Renee Hock Fund and honoraria from Britannia Pharmaceuticals, Profile Pharma, UCB, Roche, BIAL, STADA, Nordiclnfu Care, and NeuroDerm. JFR, DM and PSS are employed by BIAL - Portela & Cª, S.A.
